BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34191813)

  • 1. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
    Ibáñez-Sanz G; Milà N; Vidal C; Rocamora J; Moreno V; Sanz-Pamplona R; Garcia M;
    PLoS One; 2021; 16(6):e0253369. PubMed ID: 34191813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the faecal immunochemical test on colorectal cancer survival.
    Gutierrez-Stampa MA; Aguilar V; Sarasqueta C; Cubiella J; Portillo I; Bujanda L
    BMC Cancer; 2020 Jul; 20(1):616. PubMed ID: 32611328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
    Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
    Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study.
    Tran TN; Hoeck S; De Schutter H; Janssens S; Peeters M; Van Hal G
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.
    Idigoras Rubio I; Arana-Arri E; Portillo Villares I; Bilbao Iturribarrria I; Martínez-Indart L; Imaz-Ayo N; de la Cruz M; de Castro V; López de Munain A; Torrejón Perez I; Gutiérrez-Ibarluzea I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):197-204. PubMed ID: 30543575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
    Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
    Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening.
    Steele RJ; Kostourou I; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser C
    BMJ; 2010 Oct; 341():c5531. PubMed ID: 20980376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with symptom- and screening-detected colorectal cancer.
    Brenner H; Jansen L; Ulrich A; Chang-Claude J; Hoffmeister M
    Oncotarget; 2016 Jul; 7(28):44695-44704. PubMed ID: 27213584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
    Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
    [No Abstract]   [Full Text] [Related]  

  • 20. A comprehensive assessment of the impact of a colorectal cancer screening program in a northern Italian area.
    Pancheri S; Pertile R; Armelao F; Rizzello RV; Piffer S; Zorzi M; Guzzinati S; Ferro A; Mantovani W; de Pretis G
    Dig Liver Dis; 2022 Mar; 54(3):400-406. PubMed ID: 33853757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.